This is consistent, the team said, with the prevailing hypothesis suggesting that [semaglutides] therapeutic effects arise from overlapping neurobiological mechanisms that modulate both metabolic regulation and reward-related pathways shared between obesity and alcohol use disorder. The team concluded: Findings from this trial provide support for broadening the indication for semaglutide to [include] AUD in patients with a BMI of 30 or greater, which could benefit millions. About 890 million adults globally have a BMI over 30, and in the U.S., 8 million adults are estimated to have obesity and high alcohol consumption
All medication costs below are in addition to the $49$79/month membership fee
These compounded preparations are not FDA-approved, have not undergone the rigorous testing required for FDA approval, and may differ in purity, potency, quality, and sterility from the brand-name products
When it's prescribed specifically for weight loss, coverage is far more limited
Study: Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial